NEW YORK, Sept.

Acusphere, Inc. (NASDAQ: ACUS) announced that additional analyses from its Phase 3 clinical trials of Imagify(TM) (Perflubutane Polymer Microspheres) for Injectable Suspension were presented today at the annual American Heart Association Scientific Sessions in New Orleans, Louisiana.

Acusphere, Inc. (NASDAQ:ACUS) today announced the signing of a definitive agreement with Cephalon, Inc.

Acusphere, Inc.

Acusphere Inc. (NASDAQ: ACUS) announced today that it has reduced its employee base by 24 people, or about 24%, primarily in functions related to manufacturing of its lead product candidate, Imagify(TM) (Perflubutane Polymer Microspheres) for Injectable Suspension.